|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
EP3532464A4
(en)
|
2016-10-28 |
2020-07-08 |
Icahn School of Medicine at Mount Sinai |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
|
|
IL290809B2
(en)
*
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
BR112019015484A2
(pt)
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
KR102014478B1
(ko)
*
|
2017-05-12 |
2019-08-26 |
한국화학연구원 |
신규한 피페리딘-2,6-디온 유도체 및 이의 용도
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
TWI791552B
(zh)
|
2017-07-10 |
2023-02-11 |
美商西建公司 |
抗增生化合物及其使用方法
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
CN111278816B
(zh)
|
2017-09-04 |
2024-03-15 |
C4医药公司 |
二氢喹啉酮
|
|
CN118206529A
(zh)
|
2017-09-04 |
2024-06-18 |
C4医药公司 |
二氢苯并咪唑酮
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
|
US11028088B2
(en)
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
|
EP3774804A1
(en)
|
2018-03-26 |
2021-02-17 |
Novartis AG |
N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
|
|
JP2021519337A
(ja)
|
2018-03-26 |
2021-08-10 |
シー４ セラピューティクス， インコーポレイテッド |
Ｉｋａｒｏｓの分解のためのセレブロン結合剤
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
US20190300521A1
(en)
|
2018-04-01 |
2019-10-03 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
CA3095912A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN119751456A
(zh)
|
2018-04-16 |
2025-04-04 |
C4医药公司 |
螺环化合物
|
|
CN118344338A
(zh)
|
2018-04-23 |
2024-07-16 |
细胞基因公司 |
取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
|
|
WO2019222272A1
(en)
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
US12060366B2
(en)
|
2018-06-29 |
2024-08-13 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
CA3102212A1
(en)
|
2018-06-29 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Immunomodulatory compounds
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
CN108774215A
(zh)
*
|
2018-08-15 |
2018-11-09 |
翟学旭 |
含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
MX2021001957A
(es)
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
EP3848371A4
(en)
*
|
2018-09-07 |
2022-06-08 |
Medshine Discovery Inc. |
TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
US12227488B2
(en)
*
|
2018-12-03 |
2025-02-18 |
Dana-Farber Cancer Institute, Inc. |
Small molecule degraders of Helios and methods of use
|
|
US11325889B2
(en)
*
|
2018-12-19 |
2022-05-10 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
PL3897636T3
(pl)
|
2018-12-19 |
2025-04-28 |
Celgene Corporation |
Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi
|
|
CN120698983A
(zh)
*
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
JP7555938B2
(ja)
*
|
2019-01-30 |
2024-09-25 |
モンテリノ・セラピューティクス・インコーポレイテッド |
アンドロゲン受容体を標的とするユビキチン化のための二官能性化合物および方法
|
|
WO2020162725A1
(ko)
*
|
2019-02-07 |
2020-08-13 |
한국화학연구원 |
표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220143183A1
(en)
*
|
2019-02-23 |
2022-05-12 |
New York University |
Photoswitchable protacs and synthesis and uses thereof
|
|
WO2020181232A1
(en)
|
2019-03-06 |
2020-09-10 |
C4 Therapeutics, Inc. |
Heterocyclic compounds for medical treatment
|
|
TWI875749B
(zh)
|
2019-04-05 |
2025-03-11 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
|
WO2020206608A1
(en)
|
2019-04-09 |
2020-10-15 |
Ranok Therapeutics (Hangzhou) Co., Ltd. |
Methods and compositions for targeted protein degradation
|
|
US12414995B2
(en)
|
2019-04-16 |
2025-09-16 |
Northwestern University |
Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer
|
|
KR20220004100A
(ko)
*
|
2019-04-18 |
2022-01-11 |
하이노바 파마슈티컬스 인코포레이티드 |
안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도
|
|
CN118908962A
(zh)
|
2019-05-06 |
2024-11-08 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
WO2020251969A1
(en)
*
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
CN119954801A
(zh)
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
IL320609A
(en)
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
CA3151824A1
(en)
*
|
2019-08-27 |
2021-03-04 |
The Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
|
EP4043455A4
(en)
*
|
2019-09-12 |
2023-09-20 |
Medshine Discovery Inc. |
BICYCLIC COMPOUND AS A CRBN PROTEIN REGULATOR
|
|
JP2022548095A
(ja)
*
|
2019-09-16 |
2022-11-16 |
ノバルティス アーゲー |
接着分解剤及びその使用方法
|
|
CR20220105A
(es)
*
|
2019-09-16 |
2022-06-13 |
Novartis Ag |
Degradadores bifuncionales de brd9 y sus métodos de uso
|
|
EP4038066A1
(en)
|
2019-10-01 |
2022-08-10 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
CN115397821B
(zh)
|
2019-10-17 |
2024-09-03 |
阿尔维纳斯运营股份有限公司 |
含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
|
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN110885332B
(zh)
*
|
2019-12-06 |
2022-03-18 |
中国人民解放军第二军医大学 |
一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
GB201918414D0
(en)
|
2019-12-13 |
2020-01-29 |
Z Factor Ltd |
Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP2023507172A
(ja)
*
|
2019-12-17 |
2023-02-21 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
タンパク質分解の調節
|
|
CA3165168A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
BR112022011827A2
(pt)
|
2019-12-20 |
2022-08-30 |
C4 Therapeutics Inc |
Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
CA3162523A1
(en)
|
2019-12-23 |
2021-07-01 |
Hongfu LU |
Protein degradation agent compound preparation method and application
|
|
JP2023511280A
(ja)
*
|
2020-01-14 |
2023-03-17 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
内因性の脱ユビキチン化酵素をリダイレクトすることによる標的化されたタンパク質の安定化のための組成物及び方法
|
|
TW202140475A
(zh)
*
|
2020-01-16 |
2021-11-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用
|
|
WO2021143822A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
并环酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
KR20260017503A
(ko)
|
2020-02-14 |
2026-02-05 |
길리애드 사이언시즈, 인코포레이티드 |
Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
|
|
EP4107158A1
(en)
|
2020-02-19 |
2022-12-28 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CA3173262A1
(en)
|
2020-02-26 |
2021-09-02 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (trk) degradation compounds and methods of use
|
|
EP3875456A1
(en)
*
|
2020-03-02 |
2021-09-08 |
Technische Universität Darmstadt |
Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
|
|
CN111249276B
(zh)
*
|
2020-03-05 |
2021-07-13 |
南京巴傲得生物科技有限公司 |
吲哚布洛芬制备cbp溴区抑制试剂的用途
|
|
AU2021231898A1
(en)
|
2020-03-05 |
2022-10-27 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of BRD9
|
|
US20230123104A1
(en)
*
|
2020-03-06 |
2023-04-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound acting on crbn protein and preparation method therefor
|
|
CN113387931A
(zh)
*
|
2020-03-13 |
2021-09-14 |
四川海思科制药有限公司 |
一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
|
|
WO2021185291A1
(zh)
*
|
2020-03-17 |
2021-09-23 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
JP2023518202A
(ja)
*
|
2020-03-18 |
2023-04-28 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ｐｅｔトレーサーｐｂｂ３に基づく異常タウの標的化ディグレーダー
|
|
US12528785B2
(en)
|
2020-03-19 |
2026-01-20 |
Kymera Therapeutics, Inc. |
MDM2 degraders and uses thereof
|
|
US20230158158A1
(en)
*
|
2020-03-27 |
2023-05-25 |
Uppthera |
Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
|
|
WO2021210878A1
(ko)
*
|
2020-04-17 |
2021-10-21 |
광주과학기술원 |
Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
|
|
CN113563414B
(zh)
*
|
2020-04-29 |
2022-08-12 |
泰比棣医药科技(石家庄)有限公司 |
一种组织靶向的蛋白靶向降解化合物及其用途
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
US20230357249A1
(en)
*
|
2020-05-14 |
2023-11-09 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
AU2021275146A1
(en)
*
|
2020-05-21 |
2022-09-29 |
Dana-Farber Cancer Institute, Inc. |
Piperidine-2,6-diones as small molecule degraders of Helios and methods of use
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN113801098B
(zh)
*
|
2020-06-12 |
2023-05-30 |
上海济煜医药科技有限公司 |
酞嗪酮类化合物及其制备方法和医药用途
|
|
WO2021255212A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Braf degraders
|
|
CA3178172A1
(en)
*
|
2020-06-22 |
2021-12-30 |
Eric Fischer |
Protein tag to induce ligand dependent degradation of protein/protein-fusions
|
|
KR102559329B1
(ko)
*
|
2020-07-02 |
2023-07-25 |
포항공과대학교 산학협력단 |
신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
|
|
WO2022007903A1
(zh)
*
|
2020-07-09 |
2022-01-13 |
四川海思科制药有限公司 |
一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
|
|
WO2022019597A1
(ko)
*
|
2020-07-21 |
2022-01-27 |
주식회사 유빅스테라퓨틱스 |
안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
|
|
KR20220014952A
(ko)
*
|
2020-07-29 |
2022-02-08 |
한국화학연구원 |
안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
|
|
KR20230048373A
(ko)
*
|
2020-08-03 |
2023-04-11 |
캡터 테라퓨틱스 에스.에이. |
저분자량 단백질 분해제 및 이의 응용
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
TWI833104B
(zh)
*
|
2020-08-05 |
2024-02-21 |
大陸商上海領泰生物醫藥科技有限公司 |
靶向蛋白降解化合物及其製備方法和應用
|
|
JP7834721B2
(ja)
|
2020-08-28 |
2026-03-24 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
WO2022066835A1
(en)
|
2020-09-23 |
2022-03-31 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
|
|
EP4221756A1
(en)
*
|
2020-09-30 |
2023-08-09 |
Astrazeneca AB |
Compounds and their use in treating cancer
|
|
CN116457339A
(zh)
*
|
2020-10-14 |
2023-07-18 |
C4医药公司 |
用于医学治疗的降解新底物的三环化合物
|
|
AU2021365850A1
(en)
|
2020-10-21 |
2023-06-08 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor protein
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
CN114621231B
(zh)
*
|
2020-12-14 |
2025-09-12 |
杭州中美华东制药有限公司 |
一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
EP4289841A4
(en)
*
|
2021-02-04 |
2025-02-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Benzo seven-membered ring bifunctional compound and application thereof
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
US20240383868A1
(en)
*
|
2021-02-19 |
2024-11-21 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
CN116940571A
(zh)
*
|
2021-03-15 |
2023-10-24 |
诺华股份有限公司 |
苯并异噁唑衍生物及其用途
|
|
EP4308559A1
(en)
*
|
2021-03-15 |
2024-01-24 |
Novartis AG |
Benzisoxazole derivatives and uses thereof
|
|
KR20230160299A
(ko)
|
2021-03-23 |
2023-11-23 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체 표적화 화합물
|
|
MX2023011166A
(es)
*
|
2021-03-29 |
2023-09-29 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
US20240217968A1
(en)
*
|
2021-03-31 |
2024-07-04 |
Duke Street Bio Limited |
Pharmaceutical compound
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
CN117279910A
(zh)
|
2021-04-16 |
2023-12-22 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
CN113603676B
(zh)
*
|
2021-04-28 |
2022-05-24 |
浙江工业大学 |
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
|
|
US12006314B2
(en)
*
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20240017814A
(ko)
|
2021-05-05 |
2024-02-08 |
바이오젠 엠에이 인코포레이티드 |
브루톤 티로신 키나제의 분해를 표적으로 하는 화합물
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
WO2022250350A1
(ko)
*
|
2021-05-26 |
2022-12-01 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102474999B1
(ko)
*
|
2021-05-26 |
2022-12-07 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
JP2024519628A
(ja)
*
|
2021-05-26 |
2024-05-21 |
イノキュア セラピューティクス インコーポレイテッド |
ピペリジンジオン誘導体
|
|
KR102489160B1
(ko)
*
|
2021-05-26 |
2023-01-18 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022255889A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2022255890A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022261250A1
(en)
|
2021-06-08 |
2022-12-15 |
C4 Therapeutics, Inc. |
Therapeutics for the degradation of mutant braf
|
|
EP4359404A4
(en)
*
|
2021-06-25 |
2025-06-04 |
Celgene Corporation |
Cereblon-binding compounds, compositions thereof and methods of treatment therewith
|
|
EP4359407A4
(en)
*
|
2021-06-25 |
2025-04-30 |
Celgene Corporation |
CEREBLON-BINDING COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT USING THEM
|
|
JP2024526192A
(ja)
*
|
2021-06-25 |
2024-07-17 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
KR20240035526A
(ko)
|
2021-07-07 |
2024-03-15 |
바이오젠 엠에이 인코포레이티드 |
Irak4 단백질의 분해를 표적하는 화합물
|
|
WO2023283372A1
(en)
|
2021-07-07 |
2023-01-12 |
Biogen Ma Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
KR20240035820A
(ko)
|
2021-07-09 |
2024-03-18 |
플렉시움 인코포레이티드 |
Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
|
|
EP4157849A4
(en)
*
|
2021-08-10 |
2024-12-11 |
Uppthera, Inc. |
NOVEL PLK1 DEGRADATION-INDUCING COMPOUND
|
|
US20250171417A1
(en)
*
|
2021-08-11 |
2025-05-29 |
Xizang Haisco Pharmaceutical Co., Ltd. |
Heterocyclic derivative, and composition and pharmaceutical use thereof
|
|
FI4367118T3
(fi)
|
2021-08-18 |
2025-04-09 |
Nurix Therapeutics Inc |
Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
|
|
CA3229646A1
(en)
*
|
2021-08-23 |
2023-03-02 |
Zhengqing YE |
Irak4 degradation agent, and preparation method therefor and use thereof
|
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
WO2023056443A1
(en)
*
|
2021-10-01 |
2023-04-06 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
WO2023059792A1
(en)
*
|
2021-10-06 |
2023-04-13 |
C4 Thrapeutics, Inc. |
Coronavirus non-structural protein 3 degrading compounds
|
|
AU2022370021B2
(en)
*
|
2021-10-22 |
2026-04-16 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
|
WO2023081452A1
(en)
*
|
2021-11-05 |
2023-05-11 |
University Of South Carolina |
Small-molecule degraders of cdk8 and cdk19
|
|
CA3238118A1
(en)
*
|
2021-11-18 |
2023-05-25 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Fused imide derivative
|
|
WO2023096987A1
(en)
|
2021-11-24 |
2023-06-01 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
JP2024541480A
(ja)
|
2021-11-24 |
2024-11-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｂｒｍ標的化化合物及び関連使用方法
|
|
JP2024543129A
(ja)
|
2021-11-25 |
2024-11-19 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
アンドロゲン受容体タンパク質の標的分解のためのキメラ化合物、その調製方法及びその医薬的使用
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
CN119301111A
(zh)
*
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2023212599A2
(en)
*
|
2022-04-26 |
2023-11-02 |
Endotarget Inc. |
Compounds and methods for targeted degradation of estrogen receptors
|
|
JP2025523393A
(ja)
|
2022-06-06 |
2025-07-23 |
シーフォー セラピューティクス， インコーポレイテッド |
二環式置換グルタルイミドセレブロンバインダー
|
|
AU2023300784A1
(en)
*
|
2022-06-30 |
2025-01-02 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
KR20250047743A
(ko)
*
|
2022-07-12 |
2025-04-04 |
리젠츠 오브 더 유니버시티 오브 미시간 |
에스트로겐 수용체 분해제로서의 테트라하이드로나프탈렌 유도체
|
|
CN116496253B
(zh)
*
|
2022-08-19 |
2024-10-11 |
中国人民解放军军事科学院军事医学研究院 |
c-MET蛋白靶向降解剂及其医药应用
|
|
CN115089588A
(zh)
*
|
2022-08-22 |
2022-09-23 |
云南大学 |
达沙布韦作为e3连接酶新型配体构建protac的应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054953A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054955A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
CN118019736A
(zh)
*
|
2022-09-08 |
2024-05-10 |
标新生物医药科技(上海)有限公司 |
基于cereblon蛋白设计的分子胶化合物及其应用
|
|
CN120303264A
(zh)
|
2022-09-09 |
2025-07-11 |
医诺康治疗公司 |
CK1α和双重CK1α/GSPT1降解化合物
|
|
CN119855812A
(zh)
*
|
2022-09-14 |
2025-04-18 |
海南先声再明医药股份有限公司 |
多并环类化合物及其用途
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024073475A1
(en)
*
|
2022-09-27 |
2024-04-04 |
Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. |
Cereblon ligands and uses thereof
|
|
US20260098027A1
(en)
*
|
2022-09-29 |
2026-04-09 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method
|
|
WO2024067793A1
(zh)
*
|
2022-09-29 |
2024-04-04 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
JP2026500894A
(ja)
|
2022-10-24 |
2026-01-09 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体の標的分解のための化合物及び方法
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
KR20240076745A
(ko)
*
|
2022-11-22 |
2024-05-30 |
주식회사 이노큐어테라퓨틱스 |
신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
WO2024112122A1
(ko)
*
|
2022-11-22 |
2024-05-30 |
주식회사 이노큐어테라퓨틱스 |
Brd 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
JP2025538556A
(ja)
*
|
2022-11-22 |
2025-11-28 |
イノキュア セラピューティクス，インコーポレイテッド |
Ｃｍｅｔタンパク質を分解するための分解剤、およびそれを含む薬学的組成物
|
|
WO2024123195A1
(en)
*
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
JP2025540970A
(ja)
*
|
2022-12-06 |
2025-12-17 |
キャプター セラピューティクス エス．エー． |
ユビキチンリガーゼ及びターゲットｍｃｌ－１タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024153025A1
(zh)
*
|
2023-01-16 |
2024-07-25 |
南京明德新药研发有限公司 |
取代的苯并七元环化合物及其应用
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
KR20250145679A
(ko)
*
|
2023-02-16 |
2025-10-13 |
브리스톨-마이어스 스큅 컴퍼니 |
Ret 키나제의 분해제로서의 이소인돌리논 글루타르이미드 및 페닐 글루타르이미드 유사체
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
US20240374588A1
(en)
|
2023-04-07 |
2024-11-14 |
Astrazeneca Ab |
Irak4 protacs
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
AU2024256729A1
(en)
*
|
2023-04-20 |
2025-09-25 |
Auron Therapeutics, Inc. |
Technologies targeting cell states
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
CN119451952A
(zh)
*
|
2023-06-01 |
2025-02-14 |
标新生物医药科技(上海)有限公司 |
氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用
|
|
EP4722206A1
(en)
*
|
2023-06-01 |
2026-04-08 |
Haihe Biopharma Co., Ltd. |
Benzo(hetero)cycloalkyl compounds for androgen receptor-dependent diseases
|
|
CN120202200A
(zh)
*
|
2023-06-01 |
2025-06-24 |
标新生物医药科技(上海)有限公司 |
基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
|
|
TW202515566A
(zh)
|
2023-06-14 |
2025-04-16 |
瑞典商阿斯特捷利康公司 |
Ｓｍａｒｃａ２降解劑及其用途
|
|
MX2025015084A
(es)
|
2023-06-14 |
2026-02-03 |
Astrazeneca Ab |
Degradadores de smarca2 y usos de estos
|
|
AU2024312123A1
(en)
*
|
2023-06-23 |
2026-01-08 |
Fox Chase Chemical Diversity Center, Inc. |
Targeted degraders of hiv-1 nef for the treatment of hiv disease
|
|
AU2024307234A1
(en)
|
2023-06-30 |
2026-01-29 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025006783A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
WO2025011623A1
(zh)
*
|
2023-07-12 |
2025-01-16 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025036489A1
(zh)
|
2023-08-17 |
2025-02-20 |
海思科医药集团股份有限公司 |
一种氰基芳香环衍生物及其在医药上的应用
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
CN119613374A
(zh)
*
|
2023-09-14 |
2025-03-14 |
中国科学院上海药物研究所 |
吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
IL326555A
(en)
|
2023-09-22 |
2026-04-01 |
Glaxosmithkline Ip Dev Ltd |
Androgen receptor protax
|
|
CN121925410A
(zh)
|
2023-09-29 |
2026-04-24 |
第一三共株式会社 |
3-苯基丙胺衍生物
|
|
WO2025075693A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Purdue Research Foundation |
Shp2 degraders for cancer therapy
|
|
WO2025096855A1
(en)
|
2023-11-02 |
2025-05-08 |
Kumquat Biosciences Inc. |
Degraders and uses thereof
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250177539A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025136129A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025188857A1
(en)
*
|
2024-03-05 |
2025-09-12 |
University Of Florida Research Foundation, Incorporated |
Hdac8 degraders and uses thereof
|
|
TW202543650A
(zh)
|
2024-03-08 |
2025-11-16 |
美商海爾達醫療運營公司 |
異雙官能化合物及其在治療疾病中之用途
|
|
WO2025212557A1
(en)
*
|
2024-04-01 |
2025-10-09 |
The Johns Hopkins University |
Delivery of aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
KR20260001534A
(ko)
*
|
2024-06-27 |
2026-01-05 |
한미약품 주식회사 |
신규한 이종이작용기 단백질 분해제 및 이의 용도
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN119241498B
(zh)
*
|
2024-09-26 |
2026-04-07 |
天津科技大学 |
一种具有抗mash活性的acly靶向protac嵌合体、方法和应用
|